|
Biogen Idec to share latest neurology data at AAN 2014
Zenopa Further information will be shared on products such as Tysabri, Avonex, Fampyra, Anti-LINGO-1 and daclizumab high-yield process. Dr Alfred Sandrock, group senior vice-president and chief medical officer at Biogen Idec, said: “The breadth of data we are … |
|
Is Biogen A Value Stock Yet?
Seeking Alpha Daclizumab is being developed under a collaboration agreement with Abbvie Biotherapeutics. X. X. X. GA101 (HUMANIZED ANTI-CD20 MAB) Non-Hodgkin’s Lymphoma. Humanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is … Biogen Idec to share latest neurology data at AAN 2014Zenopa |
New Drug Cocktail Should Boost AbbVie SharesBarron’sIn fact, AbbVie has eight other drugs in late-stage clinical trials besides its hepatitis C portfolio, including a promising leukemia drug known as ABT-199 and the multiple sclerosis treatment, dacliz…
|
Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …
Jutia Group Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical … |
|
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
The Herald | HeraldOnline.com (press release) Daclizumab high-yield process (DAC HYP) is in late-stage clinical development for the treatment of RRMS, the most common form of MS. DAC HYP is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at high levels on … Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …Jutia Group |
|
Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting
Benzinga … beta-1a) and FAMPYRA® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033). |
|
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
MarketWatch Daclizumab high-yield process (DAC HYP) is in late-stage clinical development for the treatment of RRMS, the most common form of MS. DAC HYP is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at high levels on … Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …Jutia Group |
|
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
Business Wire (press release) … beta-1a) and FAMPYRA® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033). |
|
Company Update: Biogen Idec Inc (NASDAQ:BIIB) – US FDA approves Biogen’s …
Jutia Group Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical … |
|
Can AbbVie’s Legacy Products Deliver Further Growth?
Motley Fool … death) being studied in hematologic malignancies, including chronic lymphocytic leukemia; and an experimental new drug treatment offering multifactorial immunomodulatory effects for people with relapsing, remitting multiple sclerosis, called … |